ARTICLE / CLIENT ALERT / US POLICY
Biden Administration Foreshadows Impending Nursing Home Quality Reforms
March 11, 2022
Read time: 9 min
On February 28, 2022, the White House issued a fact sheet outlining several efforts aimed to increase safety, accountability, oversight and transparency in the senior services industry (Fact Sheet). Although the Fact Sheet’s initiatives have not yet been implemented, President Biden reiterated his administration’s focus on nursing home reform during his March 1, 2022, State of the Union address. Accordingly, the efforts described in the Fact Sheet provide stakeholders with a peek into the regulatory crystal ball of the governmental efforts that may be forthcoming, either through new laws, regulatory action, policy changes, enforcement activities or subregulatory guidance.
On February 28, 2022, the White House issued a fact sheet outlining several efforts aimed to increase safety, accountability, oversight and transparency in the senior services industry (Fact Sheet). Although the Fact Sheet’s initiatives have not yet been implemented, President Biden reiterated his administration’s focus on nursing home reform during his March 1, 2022, State of the Union address, stating that “Medicare is going to set higher standards for nursing homes and make sure your loved ones get the care they deserve and that they expect.” Accordingly, the efforts described in the Fact Sheet provide stakeholders with a peek into the regulatory crystal ball of the governmental efforts that may be forthcoming, either through new laws, regulatory action, policy changes, enforcement activities or subregulatory guidance. We highlight the Fact Sheet’s proposals in this alert.
1. Ensuring taxpayer dollars support nursing homes that provide safe, adequate and dignified care
The Fact Sheet describes four new initiatives that aim to improve quality of care in nursing homes. The most significant initiatives address minimum staffing requirements and the promotion of single-occupancy rooms. Though the final form of these initiatives is yet to be determined, the Centers for Medicare & Medicaid Services (CMS) has stated that it intends to accomplish these objectives through a combination of requirements and incentives.
- Minimum Nursing Home Staffing Requirements. Within the next year, CMS plans to issue a proposed rule regarding minimum staffing requirements for nursing homes. This rule will consider both staff-patient ratios and the types of staffing necessary to ensure quality care at nursing homes. Prior to issuing the proposed rule, CMS will undertake a new research study on staffing levels and quality of care outcomes. This rule is likely to be the most significant – and burdensome – policy priority outlined in the statement. At this time, it is not clear whether the proposed rule will be a blanket policy, or whether it will include staffing variation by region, care programs, or other factors. Regardless, we anticipate that compliance with the eventual final rule could result in significant operational changes for nursing homes.
- Promoting Single-Occupancy Rooms. CMS intends to “explore” ways to promote single-occupancy rooms for nursing home residents and accelerate phase-outs of rooms with three or more residents. This initiative is most clearly responsive to COVID-19 infection control challenges. Though CMS has not indicated how it will implement this initiative, this could result in a number of potential rules, such as incentive payments based on single-occupancy rooms, or possible caps on multi-occupancy rooms through life safety or other environment of care-focused requirements.
- Skilled Nursing Facility Value-Based Purchasing Program (SNF-VBP) Expansion. Currently, the SNF-VBP financially awards SNFs for performance quality of care measures, which are primarily measured by hospital readmission rates. As part of the initiative, CMS will expand the SNF-VBP to incentivize other quality performance measures, including (i) staff turnover rates; (ii) weekend staffing levels; (iii) measures that capture the resident experience; and (iv) staffing adequacy.
- Further Reducing the Use of Antipsychotic Drugs in Nursing Homes. This measure is targeted at reducing what CMS considers to be the over-use of antipsychotic medications in nursing homes. This measure can be seen as a complement to the CMS National Partnership to Improve Dementia Care in Nursing Homes, which targets antipsychotic drug prescribing practices as part of a broader effort to promote person-centered care for people with dementia.
2. Enhancing accountability and oversight
Another of the Biden administration’s priorities is enhancing accountability and oversight of nursing homes by pursuing the following initiatives:
- Adequately Funding Inspection Activities and Increasing Scrutiny on a Greater Number of the Poorest Performers. The White House is seeking Congressional approval to provide almost $500 million to CMS to increase the frequency of health and safety inspections performed at nursing homes. Simultaneously with these inspections, CMS also intends to overhaul its existing Special Focus Facility (SFF) program, which currently identifies the poorest-performing nursing homes for enhanced scrutiny until such nursing homes are able to demonstrate adequate compliance with regulatory requirements. Potential improvements to the SFF program will include (i) a renewed focus on more quickly effectuating meaningful changes for the residents of the poorest-performing nursing homes, (ii) increasing the scope of the SFF program to investigate more facilities, and (iii) higher penalties for deficient performers, including termination from participation in federal healthcare programs.
- Increasing Penalties. The Fact Sheet also announces intentions to increase penalties for poor-performing nursing homes, in the form of per-day fines becoming the default enforcement mechanism, while simultaneously increasing the ceiling of those per-day fines from $21,000 to $1,000,000.
- Increasing Accountability for Owners of Substandard Facilities. In addition to the increased penalties, the Fact Sheet requests congressional approval to grant CMS new authority to ban historically non-compliant individuals and entities from contracting with federal healthcare programs for new or existing nursing homes. Such bans would be based on a review of facilities that share the same owners or operators.
- Providing Additional Technical Assistance to Nursing Homes. Lastly, CMS intends to make improved nursing home care a priority for Quality Improvement Organizations, which are contracted by CMS to assist providers with achieving meaningful quality of care improvements. This will be accomplished by expanding both (i) on-demand trainings and information sharing around best practices and (ii) evidence-based assistance related to issues exacerbated by the pandemic.
3. Increasing transparency
Increasing transparency of corporate owners and operators of nursing homes also remains a top priority for CMS, which it will effectuate by:
- Creating a Public Database of Owners and Operators. CMS intends to create a public registry of owners and operators of nursing homes and previous violations or noncompliance, easing agencies’ efforts to track and identify repeat offenders across state lines.
- Increasing Transparency of Ownership and Improvements to Nursing Home Care Compare. Along with the public registry, CMS will enhance the Nursing Home Care Compare website by tracking corporate ownership of nursing homes and reporting such ownership and operating data; displaying nursing homes’ compliance with minimum staffing ratios (described above); and making information easier to access and understand for consumers, with an emphasis on ensuring that ratings reflect verifiable (rather than self-reported) data. The White House is also requesting Congressional approval for CMS to take enforcement action against facilities that submit incorrect information.
- Examining the Impact of Private Equity. Lastly, the federal government is evaluating the relationship between private investment and the nursing home sector to examine the role played by private equity buyers, real estate investment trusts (REITs) and other for-profit investors in the nursing home space.
4. Pandemic preparedness
The COVID-19 pandemic exposed material emergency preparedness challenges experienced by nursing homes and long term care facilities (LTCF) going forward. Generally, CMS has stated its intention to integrate “lessons learned” into nursing home Requirements for Participation (Requirements). Updates may be expected in Requirements involving fire safety, infection control, and other resident-centered policies. In particular, CMS intends to increase infection prevention staffing requirements from the current standard that allows for infection prevention personnel to work part-time and/or offsite.
In the short term, the Biden administration has stated that the federal government will continue to provide and support COVID-19 testing, vaccinations, and boosters for both LTCF residents and staff and may reward facilities with higher resident vaccination and booster rates through existing quality payment programs.
CMS is also in the process of reviewing and overhauling emergency preparedness requirements at nursing homes and LTCFs, in the context of both future pandemics and weather-related natural disasters. Nursing home patient deaths following hurricanes in Louisiana and Florida have likely motivated this effort, in addition to the ongoing impact of severe weather events and climate change. Concurrently, CMS is working to “bolster the resiliency of the health care sector” in preparation for future pandemics and natural disasters. While CMS has not provided any specific direction regarding these efforts, such an initiative could address medical staff pipelines, crisis capacity at healthcare facilities, the availability of emergency funds, and other wide-reaching matters.
5. Pathways to Jobs
Recognizing the impact that the COVID-19 pandemic has had on the workforce generally, and nursing home staffing specifically, the Fact Sheet describes three efforts to alleviate labor shortages in nursing homes.
- Affordable Nurse Aide Training. CMS will require nursing homes to notify nurse aides about training reimbursement opportunities and will work with states to distribute and publicize free trainings.
- Link Medicaid Payments to Staffing. CMS will create guidance for states to promote competitive salaries and benefits and reward experience by demonstrating ways that Medicaid payments can be tied to adequate compensation.
- Launch National Nursing Career Pathways Campaign. CMS and the Department of Labor will collaborate with stakeholders to recruit and providing training to individuals interested in transitioning to nursing careers.
Conclusion
The Biden administration has lofty goals that are likely to be welcomed by nursing home quality advocates but that may be burdensome for nursing facility owners and operators to implement. As more information emerges and stakeholders have an opportunity to digest the White House’s announcements, we will continue to monitor and report any material considerations for the senior services industry.

OSHA Announces Plan to ‘Expand Its Presence’ in Certain Healthcare Facilities Treating COVID-19 Patients
ARTICLE / CLIENT ALERT
OSHA Announces Plan to ‘Expand Its Presence’ in Certain Healthcare Facilities Treating COVID-19 Patients
March 10, 2022
Read time: 6 min
Between March 9, 2022, and June 9, 2022, the US Occupational Safety and Health Administration (OSHA) will “expand its presence” in hospitals and skilled nursing facilities that treat COVID-19 patients and that were previously cited or issued Hazard Alert Letters for alleged COVID-19 violations.
WHO IS IMPACTED?
OSHA’s stated purpose is to “target[] high-hazard healthcare facilities” to “verify and assess . . . compliance actions taken” by employers to rectify prior allegations related to COVID-19 safety violations. The initiative will focus on employers’ “readiness to address any ongoing or future COVID-19 surges.”
OSHA’s memorandum explaining the initiative lists the specific NAICS codes covered by the initiative:
- 622110 General Medical and Surgical Hospitals
- 622210 Psychiatric and Substance Abuse Hospitals
- 623110 Nursing Care Facilities (Skilled Nursing Facilities)
- 623312 Assisted Living Facilities for the Elderly
DOES THIS CREATE NEW OBLIGATIONS ON HEALTHCARE EMPLOYERS?
Notably, the initiative does not create any new obligations upon healthcare employers, nor does it reinstate, or require compliance with, the now-defunct COVID-19 Healthcare Emergency Temporary Standard (Healthcare ETS), which was adopted on June 21, 2021, and largely withdrawn on December 27, 2021. The requirements under the Healthcare ETS to record employees’ positive COVID-19 cases, and to report to OSHA all COVID-19 related hospitalizations and deaths, remain in effect.
HOW WILL OSHA ENFORCE THIS INITIATIVE?
Inspections for facilities selected as part of this initiative will fall into one of three categories:
- Follow-up inspection of any prior inspection where a COVID-19-related citation or hazard alert letter (HAL) was issued;
- Follow-up or monitoring inspections for randomly selected closed COVID-19 unprogrammed activity (UPA), to include COVID-19 complaints and Rapid Response Investigations (RRIs); or
- Monitoring inspections for randomly selected, remote-only COVID-19 inspections where COVID-19-related citations were previously issued.
Each inspection will include an assessment of COVID-19 mitigation strategies, limited to the following aspects:
- Determine whether previously cited COVID-19-related violations have been corrected or are still in the process of being corrected. For follow-up inspections of closed UPA and RRIs, determine whether COVID-19-related complaint or referral items have been corrected. Review violation worksheets or UPA complaint or referral items and any employer-provided abatement-certification.
- Determine whether the employer has implemented a COVID-19 plan that includes preparedness, response and control measures for the SARS-CoV-2 virus. If this plan is a part of another emergency preparedness plan, the review should not be expanded to the entire emergency preparedness plan (i.e., a limited review addressing issues only related to exposure to SARS-CoV-2 would be adequate).
- Verify the existence and effectiveness of all control measures, including procedures for determining vaccination status by reviewing relevant records. Verification of vaccination protocols may be an indicator of a facility’s overall COVID-19 mitigation strategies. OSHA will refer any vaccination-related deficiencies to the Centers for Medicare and Medicaid Services (CMS).
- Request and evaluate the establishment’s COVID-19 log and the Injury and Illness Logs (OSHA 300 Log, OSHA 300A Summary and any applicable OSHA 301 Incident Reports) for calendar years 2020, 2021 and 2022, if available, to identify work-related cases of COVID-19.
- Review the facility’s procedures for conducting hazard assessments and protocols for personal protective equipment (PPE) use.
- Conduct a limited records review of the employer’s respiratory protection program. The records reviewed may be limited to the written respiratory protection program and fit tests, medical evaluations, and training records for the interviewed employees.
- Perform a limited, focused walkaround of areas designated for COVID-19 patient treatment or handling (common areas, walkways, and vacant treatment areas where patients have been or will be treated), including performing employee interviews to determine compliance.
The “walkaround” portion of the inspection will be less extensive than a typical inspection, limited in scope and focused on the areas of potential non-compliance listed below. The scope of an inspection may be expanded, however, where plain-view hazards are identified during the walkaround, or where information obtained from workers or worker representative(s) indicate deficiencies in compliance:
- Determine compliance under the Respiratory Protection Standard (29 CFR 1910.134), especially in areas involving close-contact work with suspected or confirmed positive COVID-19 patients, to include fit testing, medical evaluations, training and proper use of respirators; and conduct employee interviews.
- Review documentation of any procedures or efforts made by the employer to obtain and provide appropriate and adequate supplies of PPE.
- Determine whether the employer has implemented procedures for screening workers and/or any measures to facilitate physical distancing (e.g., barriers or administrative measures to encourage six-foot distancing).
- Determine whether the employer ensures the use of face coverings or facemasks by employees, and by visitors in accordance with current public health guidance from the Centers for Disease Control and Prevention (CDC) available here https://www.cdc.gov/coronavirus/2019-ncov/index.html.
WHAT ABOUT STATES WITH STATE OSHA PLANS?
The 22 states with approved State OSHA Plans are not required to implement this initiative. Federal OSHA is providing guidance to State OSHA Plans for informational purposes and consideration. As of the date of this article’s publication, no State OSHA Plans had announced an intent to adopt this initiative. Employers are encouraged to contact their McDermott Will & Emery lawyers to receive the latest information on this initiative’s impact in states with their own State OSHA Plans.
HOW CAN HEALTHCARE EMPLOYERS COMPLY WITH THIS INITIATIVE?
While healthcare employers no longer need to follow the rigorous steps laid out in the Healthcare ETS, OSHA has stated that it will accept continued compliance with the Healthcare ETS as one method of satisfying employers’ existing obligations under other OSHA regulations.
OSHA may enforce COVID-19 safety requirements under several existing requirements:
- 29 CFR Part § 1904, Recording and Reporting Occupational Injuries and Illness.
- 29 CFR § 1910.132, General Requirements-Personal Protective Equipment.
- 29 CFR § 1910.134, Respiratory Protection.
- 29 CFR § 1910.1020, Access to Employee Exposure and Medical Records.
- 29 CFR § 1910.502(q)(2)(ii) and (q)(3)(ii)-(iv), Healthcare ETS COVID-19 log and Availability of records.
- 29 CFR § 1910.502(r), Healthcare ETS Reporting COVID-19 fatalities and hospitalizations to OSHA.
- Section 5(a)(1), General Duty Clause of the OSH Act.
Healthcare facilities may continue to be subject to the CMS vaccine mandate. Employers should remain cognizant of state and local vaccine mandates and other requirements that may impact COVID safety procedures. Compliance with these measures may also be considered when OSHA assesses employers’ good-faith efforts to maintain safe and healthy workplaces.
Employers should work with outside counsel to conduct a focused, high-level assessment of any COVID safety compliance measures undertaken by healthcare facilities that may fall within the purview of OSHA’s new initiative. Although general COVID-19 safety standards are becoming more relaxed, this initiative is a clear signal from OSHA that healthcare employers must remain just as cautious as ever.

FDA Publishes Proposed Rule on National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers as Required by the Drug Supply Chain Security Act
ARTICLE / CLIENT ALERT
FDA Publishes Proposed Rule on National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers as Required by the Drug Supply Chain Security Act
March 11, 2022
Read time: 5 min
The US Food and Drug Administration (FDA) published its proposed rule National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers on February 4, 2022. The proposed rule sets national standards for the licensing of prescription drug wholesale distributors (WDDs) and third-party logistics providers (3PLs) with the goal of strengthening the security of the US drug supply chain. When finalized and effective, these licensing regulations will preempt state and local licensing standards, requirements, and regulations that are different from these federal requirements.
The deadline to submit comments to FDA on the proposed rule is June 6, 2022 (Docket No. FDA-2020-N-1663).
The Drug Supply Chain Security Act (DSCSA), enacted by Congress on November 27, 2013, as part of the Drug Quality and Security Act (DQSA), established a federal system to identify and trace certain prescription drug products through the pharmaceutical distribution supply chain in the United States. Currently, the requirements for WDDs and 3PLs vary considerably across state and local lines. In passing the DSCSA, Congress believed a uniform national standard would ameliorate this issue. Therefore, among the various requirements set forth in the DSCSA, Congress directed the FDA to establish national standards for the licensure of WDDs and 3PLs. The proposed rule withdraws and replaces the current 21 C.F.R. Part 205 in its entirety with a new Part 205 that will implement the licensure requirements of the DSCSA and govern the national licensure of WDDs and 3PLs. In addition, the DSCSA establishes the FDA as the licensing authority for WDDs and 3PLs in states that have not established a licensing program in compliance with the proposed rule. When the proposed rule is final and effective, every U.S. WDD and 3PL will be held to these standards.
The DSCSA includes a provision that preempts states and localities from establishing or continuing requirements for WDD or 3PL licensure that are different from the national standards and requirements. The FDA has interpreted this to mean that the national licensure standards will establish both a “floor” and a “ceiling.” However, the proposed rule declares that state and local licensure requirements that differ from the national standards and requirements applicable under the Federal Food, Drug, and Cosmetic Act will not be preempted until the proposed rule is finalized and effective. This is because the “standards and requirements” that will preempt state and local law in this respect will be established by the proposed rule. The proposed rule will preempt state and local licensure requirements for WDDs two years after it becomes final and one year after it becomes final for 3PLs. However, the FDA declared that it does not intend to enforce the licensing requirements for 3PLs until two years after the proposed rule becomes final. Accordingly, state and local licensing of WDDs and 3PLs may continue in the interim period. In addition, areas within the historical police powers of the states will be unaffected by the proposed rule, including prohibiting employees of WDDs and 3PLs from engaging in criminal conduct related to prescription drugs, provided that these state requirements are not related to licensure of WDDs or 3PLs.
The key provisions of the proposed rule include the following:
- Definitions of additional terms to help clarify the requirements of the proposed rule and align with current industry practice and existing law, including “3PL activities”, “key personnel”, “minimal quantities”, “other logistics services”, “other than a consumer or patient”, “product”, and “wholesale distribution”;
- National licensure and application requirements for WDDs and 3PLs, as well as the federal licensure review process;
- Standards and procedures that set forth licensure denial, suspension, reinstatement, revocation, and voluntary termination, including notice and the opportunity to request a formal evidentiary public hearing under existing FDA hearing procedures;
- Requirements for pre-license and post-license inspections;
- Personnel requirements and qualifications necessary for licensure;
- Surety bond requirements for WDDs;
- Requirements to establish good storage practices, including personnel requirements and qualifications necessary for good storage practices compliance;
- Requirements and standards for written policies and procedures to address a product’s sale, purchase, receipt, examination, security, storage, handling, inventory, shipment, transportation, disposition, and distribution;
- Requirements, standards, and procedures for recordkeeping, document maintenance, and initial and annual reporting; and
- Requirements, standards, and procedures for the FDA’s approval of third-party accreditation or inspection services or programs (“approved organizations” or “AOs”) to review the qualifications of 3PLs for licensure and conduct inspections of 3PL and WDD facilities, including the standards and procedures for organizations whose requests for approval are denied and for AOs whose approvals are suspended or revoked.
Next Steps
FDA intends to post a webinar to provide an overview of the proposed rule to help stakeholders understand the proposed rule and prepare comments. Because the proposed rule, when final and effective, could have a significant impact on WDDs’ and 3PLs’ business operations, firms should consider submitting comments regarding how the regulations may affect their operations. As noted, the deadline to submit comments to FDA on the proposed rule is June 6, 2022 (Docket No. FDA-2020-N-1663).

The Cryptocurrency Industry Breathes a Sigh of Relief Following President Biden’s Executive Order
ARTICLE / CLIENT ALERT
The Cryptocurrency Industry Breathes a Sigh of Relief Following President Biden’s Executive Order
March 10, 2022
Read time: 6 min
On March 9, 2022, US President Joe Biden signed an unprecedented executive order directing federal agencies to coordinate their approach to clarifying cryptocurrency regulations. Sighs of relief were heard across the industry from those who feared a major blow from the White House.
The Executive Order on Ensuring Responsible Development of Digital Assets (the Order) is referred to as the “first-ever, whole-of-government approach” to the cryptocurrency industry. It lays out a national policy across six key priorities:
- Promote US competitiveness within the global cryptocurrency market
- Protect consumers and investors
- Promote financial stability
- Combat illicit finance
- Promote financial inclusion
- Promote responsible innovation.
In addition to the priorities listed above, the Order also calls for the exploration of a US Central Bank Digital Currency (CBDC).
The Order was issued for the stated purpose of “addressing the risks and harnessing the potential benefits of digital assets and their underlying technology.”
1. US LEADERSHIP IN THE GLOBAL FINANCIAL SYSTEM AND ECONOMIC COMPETITIVENESS
The Order includes a section that focuses on gaining “United States competitiveness” globally regarding the development of cryptocurrency. The Biden administration has directed the US Department of Commerce to work with relevant federal agencies to reinforce US leadership both in the global financial system and in technological and economic competitiveness to sustain US financial power and promote US economic interests. The Order also tasks the US State Department to develop ways to cooperate with international authorities to collectively promote robust standards and a level playing field in the cryptocurrency sector.
This is perhaps the most important portion of the Order. Because of the current patchwork of regulations in the United States, many cryptocurrency market participants opt to avoid the United States entirely. For this reason, the United States has not yet realized its maximum potential in the cryptocurrency space. It is hoped that this portion of the Order will ultimately result in workable regulations that fit cryptocurrency market participants of all sizes. This would welcome new market participants and put the US cryptocurrency market on an equal playing field with the rest of the world.
2. CONSUMER AND INVESTOR PROTECTION
In furtherance of the stated goal of protecting consumers, investors and businesses, the Order directs a series of regulatory agencies and other appointees to issue reports within the next 180 days. The required reports cover virtually all aspects of consumer protection, including ensuring “affordable financial services” and “cybersecurity.” President Biden is requesting “policy recommendations, including potential regulatory and legislative actions” across a broad spectrum. The Order also addresses technical issues and asks certain agencies to address the “effect of cryptocurrencies’ consensus mechanisms on energy usage.”
Consumer protection has appeared to be a primary regulatory focus of the cryptocurrency industry. We anticipate that these reports will suggest some regulatory enhancements in the areas of cybersecurity and customer protection issues.
3. FINANCIAL STABILITY
The Order directs the US Department of the Treasury (Treasury) to develop a report on the future of money and payment systems, with an eye on protecting both US and global financial stability and mitigating systemic risk. The Order repeats the general principle of “same business, same risks, same rules” and suggests that there may be increased regulatory and licensing requirements for cryptocurrency exchanges and issuers. The Order also requires reports to address “financial stability risks” and “regulatory gaps.” While the Treasury has provided some of the clearest guidance on certain regulatory regimes, such as which cryptocurrency market participants need to register as a money service business, we anticipate that these reports may provide further clarification.
4. ILLICIT FINANCE
Additionally, the Order includes a focus on eradicating illegal cryptocurrency activity. The Biden administration has called for an “unprecedented focus of coordinated action” from federal agencies in mitigating illicit finance and national security risks posed by cryptocurrencies. Federal agencies are directed to scrutinize how cryptocurrencies may undercut US sanctions and efforts to fight money laundering. The Order requires the US Attorney General, in coordination with relevant agencies, to study and report on the role law enforcement agencies may have in detecting and prosecuting criminal activity and provide recommendations on regulatory or legislative actions. The Order also urges international collaboration.
5. FINANCIAL INCLUSION
Another key objective of the Order is to reduce inefficiencies that currently exist in the US payments system while boosting financial inclusion for those who are typically underserved by the traditional banking system. The order directs the Treasury to work with relevant agencies to promote equitable access to safe, affordable and accessible financial services as a national interest.
6. PROMOTE RESPONSIBLE INNOVATION
The Biden administration stated that it aims to direct the US government to take concrete steps to support “technological advances” in developing the cryptocurrency industry. However, the Biden administration also stated that it will prioritize privacy, security, combating illicit exploitation and reducing negative climate impacts.
EXPLORATION OF A CENTRAL BANK DIGITAL SECURITY
The Biden administration will also formally consider the creation of a possible US digital currency, or a CBDC backed by the Federal Reserve System, similar to the digital currencies that were developed in other countries. While CBDCs have the potential to accelerate the settlement of payments, issues concerning financial stability and privacy remain. The Order directs the US government to assess the risks, benefits, technological infrastructure and capacity needs for such CBDCs in a manner that would protect Americans’ interests while also providing immense benefits to US communities who have suffered from insufficient access to financial services. The Federal Reserve System began working on exploring the issuance of a CBDC late last year but has yet to take a position on whether it believes the United States should issue such digital currency.
* * *
While some in the cryptocurrency industry were concerned when anticipating President Biden’s Order, it primarily calls upon certain regulators to focus on this sector. The industry will determine its true effects when these reports are delivered, and regulations are subsequently enacted. For now, the Order signifies the Biden administration’s goal to adopt regulation without frustrating innovation and to facilitate the United States’ development as a market leader in the crypto space.

Ukraine Crisis: New US Sanctions on Russia and Belarus
ARTICLE / CLIENT ALERT
Ukraine Crisis: New US Sanctions on Russia and Belarus
March 10, 2022
Read time: 13 min
In this alert, our trade and sanctions team provides an update on the latest sanctions following our February 24, 2022, alert.[1] In the interim, the United States has imposed new sanctions on Russia and Belarus in response to the deteriorating situation in Ukraine. The latest measures target specified Russian individuals with close ties to the government, expand economic sanctions targeting Russia’s and Belarus’s financial sectors, and impose new export control restrictions. These actions include asset blocking and other restrictive measures imposed by the US Treasury Department’s Office of Foreign Assets Control (OFAC), as well as new export controls imposed by the US Commerce Department’s Bureau of Industry and Security (BIS).
US FINANCIAL AND ECONOMIC RESTRICTIONS AGAINST RUSSIA
As outlined in our prior alert, the US government’s first rounds of sanctions included restrictions on secondary market transactions involving Russian sovereign debt, blocking sanctions on large Russian banks and sanctions on Russia’s Nord Stream 2 pipeline. Since then, the United States, along with its partners and allies, has announced a variety of new sanctions targeted at the Russian financial sector, Russian oligarchs with close ties to the Russian government and stringent export controls on technology, as well as sanctions against Belarus.
Recent Broad-Based Sanctions Against Russia and Belarus
On February 24, 2022, OFAC announced new financial and blocking sanctions “specifically designed to impose immediate costs and disrupt and degrade future economic activity, isolate Russia from international finance and commerce, and degrade the Kremlin’s future ability to project power.” Along with new additions to the Specially Designated Nationals and Blocked Persons (SDN) list and new frequently asked questions (FAQs), OFAC issued two directives under Executive Order (EO) 14024[2]:
- Russia Directive 2 prohibits US financial institutions from (1) processing any transaction involving any foreign financial institution named on the Correspondent Account and Payable-Through Account (CAPTA) sanctions list, and (2) opening or maintaining correspondent accounts or payable-through accounts involving or on behalf of certain foreign financial institutions designated on the CAPTA list. Currently, the list is comprised of Sberbank and 25 Sberbank subsidiaries and/or affiliates. The directive applies to foreign financial institutions that are 50% or more owned, directly or indirectly, individually or in the aggregate, by one or more foreign financial institutions determined to be subject to the directive. The effective date of Directive 2 will be March 26, 2022.
- Russia Directive 3 prohibits transactions by US persons in, provision of financing for, and other dealings involving new debt with longer than a 14 days maturity, or new equity, by 14 entities designated in Annex 1 to the directive. This directive will come into effect on March 26, 2022. These sanctions also apply to any subsidiaries in which a named entity holds an ownership interest of 50% or more, even if those subsidiaries are not identified in Directive 3.
On February 28, 2022, OFAC issued a new directive under EO 14024 aimed at further curtailing transactions with the Russian Central Bank, and it added new entities to the SDN list.
- Russia Directive 4 prohibits US persons from engaging in any transaction involving the Central Bank of the Russian Federation, the Russian Ministry of Finance and the Russian National Wealth Fund, including any transfer of assets to such entities and any foreign exchange transaction for or on behalf of such entities. The 50% rule does not apply to Directive 4.
The four directives issued so far under EO 14024 should not be confused with Directives 1–4 issued in past years under EO 13662, which were issued in response to Russia’s invasion and occupation of Crimea in 2014. Those earlier directives are still in force.
On March 2, 2022, the Federal Aviation Administration (FAA) banned all Russian air carriers and commercial operators, all Russian-registered aircraft, all Russian state aircraft, and all Russian-owned, controlled, leased or operated aircraft from operating to, from or within US territorial airspace (with an exception for emergencies and certain authorized humanitarian/rescue and diplomatic operations).
On March 3, 2022, OFAC designated as SDNs 33 individuals and seven entities associated with Russia’s global disinformation campaign, particularly those backed by Russian intelligence services. The US also imposed sanctions on 22 defense-related firms that develop and produce, for Russia’s military, fighter aircraft, infantry fighting vehicles, electronic warfare systems, missiles and unmanned aerial vehicles. Along with its EU allies, the US imposed new export controls on oil and gas extraction equipment that supports Russia’s refining capacity and introduced visa restrictions for certain Russian oligarchs and their families.
On March 8, 2022, President Biden announced a ban on importing Russian oil and gas into the United States as part of an effort to isolate Russia’s energy-heavy economy and President Putin. This action has been imposed under a new Executive Order that also includes a ban on investments by US persons in Russia’s energy sector.
OFAC General Licenses
At the same time as it issued new sanctions measures, OFAC issued a number of general licenses, described below, allowing the continuation of certain activities that would otherwise be prohibited under the new sanctions. A number of these general licenses are time-limited.
- Russia-General License 5 authorizes transactions for the official business of various international organizations including, but not limited to, the International Centre for Settlement of Investment Disputes (ICSID), the Inter-American Development Bank Group (IDB Group) and the International Committee of the Red Cross. EO 14024 already exempts transactions that are for the conduct of the official business of the United Nations by employees, grantees or contractors.
- Russia-General License 6 authorizes transactions that are ordinarily incident and necessary to (1) the exportation or re-exportation of agricultural commodities, medicine, medical devices, replacement parts and components for medical devices or software updates for medical devices to, from or transiting Russia, or (2) the prevention, diagnosis or treatment of COVID-19 (including research or clinical studies).
- Russia-General License 7 authorizes transactions that are ordinarily incident and necessary to (1) the receipt of, and payment of charges for, services rendered in connection with overflights of Russia or emergency landings in Russia by aircraft registered in the United States or owned or controlled by, or chartered to, US persons, and (2) air ambulance and related medical services, including medical evacuation, to individuals in Russia.
- Russia-General License 8 authorizes transactions involving specific entities that are related to energy, including State Corporation Bank for Development and Foreign Economic Affairs Vnesheconombank, Bank Otkritie, Sovcombank, Sberbank, VTB Bank, and any subsidiary with 50% or greater interest as long as the transactions do not involve the opening or maintaining of a correspondent account or payable-through account for or on behalf of the entities subject to Directive 2 or involve any other persons blocked pursuant to EO 14024. General License 8 is currently effective through June 24, 2022.
- On February 28, 2022, OFAC issued General License 8A, which modified General License 8 to add the Central Bank of the Russian Federation to the list of entities with which otherwise-prohibited transactions “related to energy” may be conducted.
- Russia-General License 9 authorizes, through May 25, 2022, transactions ordinarily incident and necessary to dealings in debt or equity, including facilitating, clearing and settling trades of covered debt or equity, of VEB Bank, Bank Otkritie, Sovcombank, Sberbank, VTB Bank or their majority-owned subsidiaries issued prior to February 24, 2022, provided that any divestment or transfer of, or facilitation of divestment or transfer of, such debt or equity must be to a non-US person. This general license does not authorize the opening or maintaining of a correspondent account or payable-through account or transactions involving any other persons blocked pursuant to EO 14024.
- General License 9A modified General License 9 by adding the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation to the list of entities with which otherwise-prohibited transactions may be conducted, provided that any divestment or transfer of, or facilitation of divestment or transfer of, such debt or equity must be to a non-US person. GL 9A also replaced EO 14024 with the newly issued Russian Harmful Foreign Activities Sanctions Regulations (RuHSR) as the controlling directive for purposes of General License 9. This general license does not authorize the opening or maintaining of a correspondent account or payable-through account or transactions involving any other persons blocked pursuant to the RuHSR.
- Russia-General License 10 authorizes, through May 25, 2022, transactions ordinarily incident and necessary to the wind down of derivative contracts linked to debt or equity entered into prior to 4:00 PM EST on February 24, 2022, that include VEB Bank, Bank Otkritie, Sovcombank, Sberbank, VTB Bank or any subsidiaries with 50% or greater interest as a counterparty. This general license does not authorize the opening or maintaining of a correspondent account or payable-through account or transactions involving any other persons blocked pursuant to EO 14024.
- General License 10A modified General License 10 to also authorize transactions involving the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation, that are ordinarily incident and necessary to the wind down of derivative contracts, repurchase agreements or reverse repurchase agreements entered into prior to March 1, 2022.
- Russia-General License 11 authorizes, through March 26, 2022, transactions ordinarily incident and necessary to the wind down of transactions involving Bank Otkritie, Sovcombank, VTB Bank or any subsidiary with a 50% or greater interest. This general license does not authorize any transaction involving any persons blocked (other than those mentioned above) pursuant to EO 14024.
- Russia-General License 12 authorizes, through March 26, 2022, US persons to reject (as opposed to blocking) transactions involving Bank Otkritie, Sovcombank, VTB Bank or any subsidiary with a 50% or greater interest. This general license does not authorize any transaction involving any persons blocked (other than those mentioned above) pursuant to EO 14024.
- Russia-General License 13 authorizes, through June 24, 2022, US persons to pay taxes, fees or import duties, and purchase or receive permits, licenses, registrations or certifications, to the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation, provided such transactions are ordinarily incident and necessary to such persons’ day-to-day operations in the Russian Federation and they do not involve a debit to an account on the books of a US financial.
- Russia-General License 14 authorizes transactions related to the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation, where the function in the transaction is to act as an operator of a clearing and settlement system, provided that (1) there is no transfer of assets (to or from), unless separately authorized, and (2) no entity is either a counterparty or a beneficiary to the transaction, unless separately authorized. This general license does not authorize any debit to an account on the books of a US financial institution.
- Russia-General License 15 authorizes transactions and unblocking all property of any entity owned 50% or more, directly or indirectly, by Alisher Burhanovich Usmanov, that does not appear on OFAC’s SDN list. This license does not authorize transactions involving any person blocked or otherwise sanctioned pursuant to the RuHSR, including Usmanov, or his property or interests in other properties.
- Russia-General License 16 authorizes transactions related to certain imports prohibited by the Executive Order of March 8, 2022, prohibiting certain imports and new investments with respect to continued Russian actions in Ukraine.
In addition, OFAC issued Belarus General License 6 and General License 7 to authorize certain transactions related to official business of the US government and international organizations and entities, respectively.
- Belarus-General License 6 authorizes transactions prohibited by the Belarus Sanctions Regulations, 31 CFR 548, that are for the conduct of the official business of the United States government by employees, grantees or contractors thereof.
- Belarus-General License 7 authorizes transactions prohibited by the Belarus Sanctions Regulations, 31 CFR 548, or Executive Order 14038 that are for the conduct of the official business of several humanitarian entities such as the United Nations and its affiliates and the International Red Cross.
Targeted US Sanctions
Since the beginning of the Russian invasion in Ukraine, the United States has been regularly updating its SDN list covering specified entities and individuals. US persons are prohibited from dealing with SDNs and assets of SDNs in the United States, and assets of SDNs that come within the possession of a US person must be blocked. Targeted entities include major financial institutions (such as VTB Bank, Russian Direct Investment Fund (RDIF) and two RDIF-affiliated entities), companies in key Russian sectors (such as Gazprom, Rostelecom and RusHydro) and key Russian government officials and oligarchs with close ties to the government (such as President Putin, Russian Minster of Foreign Affairs Sergei Viktorovich Lavrov and senior executive of Sberbank Alexander Vedyakhin).
US blocking requirements apply to funds and economic resources owned, held or controlled by a sanctioned person as well as entities owned or controlled directly or indirectly by sanctioned persons or the government of the Russian Federation. Thus, even if not expressly included on the SDN list, an entity will be considered as being an SDN if it is owned at least 50% by one or more SDNs (individually or in the aggregate).
OFAC also expanded on its past SDN designations[3] related to the Belarusian defense industry and violation of democratic principles, by imposing blocking sanctions on Belarusian state-owned financial institutions (Belarussian Bank of Development and Reconstruction Belinvestbank JSC (Belinvestbank)), Bank Dabrabyt JSC (one of the largest financial institutions in Belarus), and two entities closely associated with the Belarussian government (real estate firm LLC Belinvest-Engineering and financial leasing company CJSC Belbizneslizing), among other individuals related to the military and defense industry in Belarus.[4]
Export Restrictions Imposed by the US Commerce Department, Bureau of Industry and Security (BIS)
In response to Russia’s actions in Ukraine and Belarus’s support of Russia’s actions, BIS has imposed a series of new restrictions on US exports of certain items to Russia or Belarus, under which covered items may not be exported to these countries without specific export license authorization. These restrictions also extend to the Donetsk and Luhansk regions of Ukraine the same export embargo as already applies to the Crimean region of Ukraine. The new export restrictions are primarily contained in Sections 746.5, 746.6 and 746.8 of the BIS Export Administration Regulations (EAR).[5]
The new export restrictions apply to a wide range of goods, software and technology, and only limited license exceptions are available. These restrictions also apply to reexports to Russia or Belarus from third countries of US items, exports to Russia and Belarus of foreign-made items containing more than de minimis levels of US content, and exports to Russia or Belarus of certain foreign-made items that are the “direct product” of US technology.
In addition, BIS has added a large number of Russian entities to the BIS entity list. Exports or reexports to these entities are subject to significantly broader restrictions than apply under the more generally applicable export rules. As a general rule, it should be assumed that all exports and reexports that are subject to the EAR to these entities will be prohibited.
Even if an export or reexport is permissible under the new rules, parties are advised to consider how the US sanctions rules on Russian banks will affect the ability of an exporter to get paid for the exported items.
The new restrictions are complex and cannot be summarized briefly. The facts of each transaction, including the items being exported or reexported, the identity (or identities) of the end user (or users), and the end uses of the items will need to be considered.
IMPACT FOR BUSINESSES
As the scope and variety of US sanctions against Russia continues to increase, businesses will need to take swift action to limit their exposure.
- If you or your company have business relationships with Russian entities, consider whether it is viable or legal to continue such relationships, and if not, review relevant contractual agreements and take steps to terminate such relationships.
- If you or your business have a bank account with a subsidiary of a Russian sanctioned bank, consider whether you are covered by an OFAC general license to transfer funds out of the accounts.
- Implement robust sanctions screening provisions and monitor new developments.
- Seek legal advice if you are concerned about potential exposure.

Navigating the Continued Boom in Behavioral Health – Roundtable
ARTICLE
Navigating the Continued Boom in Behavioral Health – Roundtable
March 10, 2022
Read time: 5 min
In this segment, Alex Clavero and Bernie Grondin, partners in McDermott’s Healthcare Services Private Equity Practice, moderate a discussion on the demand drivers, challenges and investment opportunities in the current landscape of the behavioral health services sector.
Participants
- Alex Clavero, Partner, McDermott Will & Emery
- Bernie Grondin, Partner, McDermott Will & Emery
- L.A. Galyon IV, Managing Director and Partner, Brentwood Capital Advisors
- David Peterson, Managing Director, NMS Capital
- Kiel Rager, Founder and Chief Executive Officer, InBloom Autism Services
Key Takeaways
- Growth of the behavioral health sector is gaining momentum, as providers strive to meet rapidly increasing demand for behavioral health services. Competition for clinical staff has been and remains one of the biggest challenges across the numerous specialties that fall under the “behavioral health” umbrella. Given the shortage of clinicians compared to the demand, providers and payors have started to focus on new models to deliver treatment.
- Demand in the autism sector, for example, can be attributed to a higher prevalence of children being diagnosed with autism today than in the past. In the current market, it is estimated that only 30% of demand is being met. The biggest challenge to optimizing outcomes for kiddos (the autism sector’s term for pediatric patients) is the competition for high-quality staff. Payors are starting to focus on new models to deliver care to kiddos, including parent-led programming, a model in which providers are, effectively, training the parent to provide the services, given the lack of clinicians to meet demand.
- In the mental and behavioral health sector, there are a number of challenges that arise in the context of the traditional third-party payor model. Chief among these is a general lack of access to the mental health system. With a community-based care model, these challenges could be addressed by providing a more comprehensive approach to treatment and reimbursement.
In the current mental health landscape, the majority of outpatient psychiatrists do not take insurance, which is a product of the reimbursement rates for covered services and the types of services covered.- At current reimbursement rates, there are few psychiatric practices that can make money at the gross-profit level. To the extent insurance plans have in-network providers in a geographic area, the wait to get an appointment with one of those providers is often too long (ranging from months to years), leaving patients with out-of-network care as the only timely alternative. Furthermore, the system in place today is set up to provide acute care to psychiatric patients while they are at a facility, but not after they are released. In most other aspects of medicine, a patient receives acute care during their stay at a hospital and receives stepped-down levels of care after discharge. Psychiatry does not have an equivalent model, with inpatient acute care provided at the facility and stepped-down care delivered once a patient is released, which makes it difficult for such patients to see lasting or meaningful improvements.
- To address these challenges, payors must be educated on the need for better reimbursement and more thoughtful approaches to utilization and authorization. As an alternative service model, a community-based care approach takes a longer-term view, helping coordinate between acute-care providers and the therapists, counselors, social workers and other professionals who support patients in their efforts to achieve stability in daily life following acute-care treatment. Thus, there is an opportunity to be an early mover in the less-acute care segment of the industry and—by using a mix of telehealth, mid-level providers, ancillaries and other modalities that will be covered in-network—to create a scalable model.
- The increased prevalence of employee assistance programs (EAPs) in recent years has been a contributing factor in the rising demand for mental and behavioral health services, and has also presented a service model that has attracted considerable investment.
- On the mental health and addiction-treatment sides of the industry, particularly during the COVID-19 pandemic, there has been an increase in care provided, whether through an increased number of employers offering EAPs and/or similar benefits, more employees utilizing those resources, and the proliferation of mental health clinics and mental health support.
- Mental health has become one of the top five reasons for staff resignations in the behavioral therapy space since 2020, which underscores the importance of the new role of EAPs from a provider/operational perspective. Some companies are implementing EAPs that provide unlimited access to telehealth psychology appointments, even if they do not have insurance through the company. Given how much companies are now spending on EAPs to provide mental health and wellness resources outside of traditional health insurance, EAPs present an interesting opportunity in response to both the shortage of behavioral and mental health services covered by insurance, and the general shortage of clinical providers.

State Law Privacy Video Series | Appeals Rights
ARTICLE / CLIENT ALERT / VIDEO
State Law Privacy Video Series | Appeals Rights
March 8, 2022
Read time: 2 min
California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.
In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.
In this next video, Counsel Jessi Sawyer discusses the consumers’ rights to appeal under the California, Virginia and Colorado privacy laws. She also discusses the different requirements that organizations should be aware of when a consumer’s request is denied.


DOJ to devote substantial resources to investigating and prosecuting corporate crime, emphasizing importance of effective compliance programs
ARTICLE / CLIENT ALERT / US POLICY
DOJ to devote substantial resources to investigating and prosecuting corporate crime, emphasizing importance of effective compliance programs
March 7, 2022
Read time: 7 min
In March 3, 2022, speeches at the American Bar Association’s Annual National Institute on White Collar Crime (ABA White Collar Institute), US Attorney General (AG) Merrick Garland and US Assistant Attorney General for the Criminal Division (AAG) Kenneth Polite Jr. addressed the US Department of Justice’s (DOJ) increased commitment to investigating and prosecuting corporate crime.
As a testament to their commitment to these resource-intensive cases, AG Garland discussed plans to hire 120 new prosecutors and 900 new FBI agents; this announcement represents a substantial surge in resources. AG Garland and AAG Polite also addressed specific ways they intend to increase enforcement efforts, including through the expanded use of data analytics. Finally, in addition to outlining substantive enforcement priorities, AG Garland and AAG Polite emphasized DOJ’s focus on individual accountability, with AG Garland reiterating that DOJ’s primary goal is “obtaining individual convictions rather than accepting big-dollar corporate dispositions.”
As AG Garland warned, DOJ’s white-collar enforcement efforts will further “accelerate as we come out of the pandemic” and DOJ’s interest in corporate crime is clearly “waxing again.” Companies must therefore take proactive steps to prepare for this increased enforcement activity.
Substantial Additional Resources for Corporate Crime Enforcement
In 2021, DOJ charged 5,521 individuals with “white collar” crimes, which represented a 10% increase over 2020. During his speech, AG Garland announced that DOJ will be devoting even more resources toward its corporate crime enforcement efforts going forward. Specifically, DOJ will seek funding to hire 120 new prosecutors and 900 new FBI agents, all of whom would focus on white-collar crime. If DOJ obtains such funding, those new prosecutors and agents could supercharge DOJ’s enforcement efforts. For example, 120 prosecutors is more prosecutors than there are in many US Attorneys’ Offices (including in the District of Massachusetts, a district that is already active in corporate enforcement, particularly in the resource-intensive healthcare space). Adding 900 new FBI agents—a number that is similarly larger than many existing FBI field offices—could allow DOJ to pursue thousands of new corporate criminal investigations.
Expanded Use of Data Analytics
For the past two years, DOJ and other federal agencies have increasingly relied on sophisticated data analytics tools to identify and prosecute corporate crime. AG Garland specifically identified data analytics as another “force-multiplier” for DOJ. DOJ’s use of data analytics will undoubtedly expand going forward. Among other things, AG Garland announced that a new squad of FBI agents has been embedded within the Criminal Division’s Fraud Section to “further strengthen [DOJ’s] ability to bring data-driven corporate crime cases nationwide.” As DOJ increasingly relies on “big data,” including vast amounts of data from other state and federal agencies, companies must ensure that they are proactively using data analytics to further their own internal compliance efforts.
DOJ’s priority enforcement areas
AG Garland and AAG Polite mentioned several of DOJ’s specific white-collar criminal enforcement priorities during their remarks. In addition to traditional areas such as healthcare fraud, securities fraud and Foreign Corrupt Practices Act violations, companies should expect increased DOJ scrutiny in the following areas:
- Antitrust: AG Garland highlighted DOJ’s active investigations and prosecutions of alleged criminal antitrust violations and collusive activity in government procurement. DOJ’s Antitrust Division ended the last fiscal year with 146 open grand jury investigations—the most in 30 years—and is trying or preparing to try 18 indicted cases against 10 companies and 42 individuals. AG Garland previously noted that “reinvigorating Antitrust enforcement” was a top priority for DOJ, and he requested a budget increase of 9% for the Antitrust Division (more than $200 million). Such significant additional resources will bolster the Antitrust Division’s aggressive pursuit of alleged violations in their current priority areas: government procurement, labor markets, consumer products and the healthcare industry. In addition, during separate remarks at the ABA White Collar Institute, Richard Powers, the Deputy Assistant Attorney General for Criminal Enforcement in the Antitrust Division, noted that the Division is also prepared to criminally charge individual executives for violations of Section 2 of the Sherman Act (the provision prohibiting market monopolization). Charging Section 2 cases criminally is an exceedingly aggressive and controversial approach, and it something that the Division has not done in decades.
- COVID-19 Fraud: AG Garland reiterated DOJ’s commitment to pursuing fraudulent conduct in connection with the COVID-19 pandemic. As President Biden recently announced, AG Garland will be “naming a chief prosecutor to lead specialized teams dedicated to combatting pandemic fraud.” The chief prosecutor will “build on” the work of the COVID-19 Fraud Enforcement Task Force announced in May 2021. Additional pandemic-related prosecutions and investigations will likely continue for years to come and may increase in scope and complexity.
- Cryptocurrency: AAG Polite specifically mentioned the “emerging cryptocurrency space” as an area in which individual victims are particularly vulnerable to being “exploited by other market participants.” AAG Polite referenced the recent indictment of the founder of cryptocurrency platform BitConnect in connection with an alleged $2.4 billion Ponzi scheme. His remarks follow increased cryptocurrency enforcement and regulatory activity from the US Securities and Exchange Commission (SEC), the Financial Crimes Enforcement Network (FinCEN), the Internal Revenue Service (IRS) and other federal agencies during the past year, and they demonstrate that cryptocurrency remains squarely in the DOJ’s crosshairs.
DOJ’s Renewed Focus on Individual Accountability
The remarks of AG Garland and AAG Polite focused heavily on DOJ’s efforts to ensure that individuals are held accountable for corporate crime. AG Garland stated that DOJ’s “first priority in corporate criminal cases is to prosecute the individuals who commit and profit from corporate malfeasances.” AG Polite in turn noted that DOJ “prioritize[s] prosecution of individuals responsible for corporate crimes to the fullest extent of the law.”
Although “individual accountability” has long been at the core of DOJ’s Principles of Federal Prosecution, AG Garland and AAG Polite’s statements were noteworthy since prosecutions of individuals for corporate crime had waned during the past administration. AG Garland recognized that “obtaining individual convictions rather than accepting big-dollar corporate dispositions is a difficult and resource-intensive road,” but committed to marshalling the resources necessary for DOJ to pursue such prosecutions successfully.
AG Garland and AAG Polite also reemphasized DOJ’s requirement that, to be eligible for cooperation credit, companies must provide DOJ “with all non-privileged information” about “all individuals involved in or responsible the misconduct at issue,” regardless of “their position, status or seniority.” First announced by Deputy Attorney General (DAG) Lisa Monaco last fall, AG Garland described this requirement and defense lawyers as a “force multiplier” for DOJ. DOJ now expects companies and their defense lawyers to “come clean about everyone involved in the misconduct, at every level.” This is a change from the previous administration, which required only that companies make disclosures regarding those individuals the companies deem to have had “substantial” involvement in the misconduct.
Key takeaways
With a surge of DOJ resources focused on corporate crime (and AG Garland’s clear commitment to enforcement in that area), the importance of an effective corporate compliance plan cannot be overstated. In fall 2021, DAG Monaco reiterated the import of self-monitoring, a trend that has been gaining momentum at DOJ since it first issued comprehensive compliance guidance in 2017. AAG Polite reiterated the same on March 3, 2002, providing additional insight into what DOJ will be looking for when evaluating corporate compliance programs:
- DOJ wants to know “whether you are doing everything you can to ensure that when that individual employee is facing a singular ethical challenge, he has been informed, trained and empowered to choose right over wrong.”
- When misconduct takes places, DOJ will be evaluating whether your company has in place “a system that immediately detects, remediates, disciplines, and then adapts to ensure that others do not follow suit.”
- Even when a CEO is not involved in wrongdoing, DOJ expects corporations to “examine whether a change in leadership is necessary” and analyze whether current leadership “modeled poor ethical behavior for the workforce, or fostered a climate in which subordinates committed wrongdoing with intent to benefit the company, or permitted weak internal controls that allowed the crimes of individuals to go undetected.”

FDA Issues Final Guidance for Initiation of Voluntary Recalls
ARTICLE / CLIENT ALERT
FDA Issues Final Guidance for Initiation of Voluntary Recalls
March 7, 2022
Read time: 7 min
The US Food and Drug Administration (FDA) published its Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C: Guidance for Industry and FDA Staff (final guidance) on March 4, 2022. The final guidance describes how firms should develop and implement necessary recall plans and procedures that include training, planning and recordkeeping to effectively plan, prepare and initiate a voluntary recall in order to adequately protect the public from a product potentially violative of the Federal Food, Drug, and Cosmetic (FD&C) Act. The final guidance makes minor changes to an April 2019 draft version of the same title (draft guidance) and reflects the agency’s ongoing commitment to work closely with regulated firms to ensure that products in violation of the FD&C Act—or other laws enforced by FDA—are quickly taken off the market to protect public health.
Comments on the final guidance (Docket No. FDA-2018-D-2074) can be submitted at any time.
The final guidance clarifies the agency’s recommendations regarding how regulated firms in a product distribution chain should prepare to facilitate timely initiation of a voluntary recall, respond to an indication that there may be a problem with a distributed product, and initiate a voluntary recall. The guidance applies to voluntary recalls of products subject to FDA’s jurisdiction, including food, drugs and devices intended for human or animal use; cosmetics and biological products intended for human use; tobacco products intended for human use; and items subject to a quarantine regulation under 21 CFR Part 1240. The guidance can also inform actions by manufacturers and distributors to remove or correct a product under circumstances that would not meet the definition of a recall (e.g., market withdrawal). The final document’s minor revisions to the draft guidance include editorial changes to improve clarity, addition of the terms “correction” and “market withdrawal” to the terminology section, and addition of language encouraging the use of electronic communications for transmitting voluntary recall communications about FDA-regulated products.
Key Takeaways and Concepts
How to Be “Recall Ready”
In the final guidance, FDA emphasizes that regulated firms must be “recall ready.” This not only means that firms should make recall plans and initiation procedures that are specific to the firm or facility in advance of when a recall may be needed, but also that firms should consider writing additional plans or procedures as appropriate to suit their business. Specifically, FDA recommends firms make the following preparations in advance of when a recall may be needed:
- Identify and assign personnel recall-related responsibilities. Firms should, and sometimes must, task specific personnel with recall-related responsibilities who possess the authority to take the required steps to implement a product recall. The establishment of a “recall team” composed of a defined group of employees may be appropriate in certain situations, such as where recall efforts are particularly complex or involve other complicating factors.
- Train personnel. Personnel identified to perform recall activities should be regularly educated on recall procedures. Firms should consider additional preparatory steps, such as conducting mock recalls and establishing specific metrics appropriate to a recall plan. Modifications to procedures should be made as necessary.
- Establish a recall communications plan. This plan should contain draft templates (e.g., notification letters) and identify points of contact to help promptly issue recall communications. In the final guidance, FDA encourages the use of electronic communications, such as email, for transmitting voluntary recall communications.
- Identify potential reporting requirements. Firms should know whether there are requirements associated with their product(s) that trigger an obligation to report to FDA.
- Use appropriate product coding. Firms should use coding that allows for identification of the production and control data for each lot, batch or unit and positive lot identification to facilitate the effective recall of all violative lots. For products that have mandatory identifiers, such as blood product container label codes or medical device unique device identifiers (UDIs), these coding systems may be sufficient. For products that do not have mandatory coding or identification requirements, the agency recommends that firms develop alternate coding and identifications systems based on lot, batch or other manufacturing data.
- Maintain distribution records. Recalling firms should keep distribution records beyond the product’s shelf life and expected use in order to facilitate the location of recalled products. The maintenance period should be, at a minimum, the length of time specified in applicable records retention regulations. The records should identify the name, address and telephone number of the direct accounts that received the recalled product, and records must conform to all applicable requirements. Direct accounts that distribute the product should maintain records of their own direct accounts in turn, to ensure that the recalling firm’s instructions extend to all consignees in the chain of distribution.
Firms also should prepare, maintain and document written recall initiation procedures that assign responsibility and describe the steps necessary for initiating a recall, as appropriate to the firm or facility. The recall initiation procedures should include the following:
- Ceasing distribution, shipment or sales of affected product
- Developing a recall strategy
- Promptly and timely notifying direct accounts
- Notifying the public of a recalled product that presents a health hazard.
The final guidance builds on the draft guidance by advising firms that their recall strategy should take into account the possibility that a recall’s scope may expand if additional lots or products are affected, and by suggesting that personnel be trained on the recall initiation procedures. FDA recommends that firms with recall communications plans that allow for communications with direct accounts by telephone also require that these telephone communications be subsequently confirmed in writing.
How to Respond to an Indication of a Problem with a Distributed Product
FDA recommends that firms implement the following steps in their procedures if there is an indication of a problem with a distributed product:
- Identify the problem. Firms should implement procedures to identify indicators that there may be a problem with a distributed product. Indicators include internal reports of product specification deviations, inspectional observations and laboratory analytical results.
- Investigate the problem. The procedures should describe the steps to investigate a problem with a distributed product, including timely investigation and prompt evaluation by a qualified person following established criteria. The final guidance states that a recalling firm is not required to wait to initiate a voluntary recall until the investigation or evaluation is complete.
- Make decisions. The procedures should describe the steps necessary to control defective and potentially harmful products in a timely manner. The procedures should address the decision whether to initiate a voluntary recall and, if initiated, the appropriate scope and depth of the recall.
- Consult with FDA. Firms should engage with FDA while the investigation is ongoing. FDA recall coordinators are the agency points-of-contact for recalling firms. FDA recall coordinators can also assist by referring recalling firms to other government agencies that are primarily responsible for monitoring the product recall. Firms can visit FDA’s website for FDA recall coordinators’ contact information.
- Initiate a voluntary recall. Firms can initiate a voluntary recall by promptly notifying the affected direct accounts and by issuing a press release or other public notice, if appropriate. The final guidance recommends that a recalling firm conduct follow-up communications with direct accounts that fail to respond to a recall communication. FDA considers the date of a firm’s first communication about a recall, either to its direct accounts or to the public, to constitute the date of initiation. FDA recommends that a recalling firm follow the initiation procedures in its recall plan to implement the recall in accordance with 21 CFR § 7.46 (firm-initiated recall). A recalling firm is not required to delay initiation of a voluntary recall pending FDA’s review of its recall strategy or communications.
Next Steps
The final guidance presents a helpful framework for firms to prepare to quickly and effectively implement recall procedures. Stakeholders should consider reviewing their current recall plans and procedures in light of the final guidance.

The Significance of Recent Delaware Court of Chancery SPAC Opinions
ARTICLE / CLIENT ALERT
The Significance of Recent Delaware Court of Chancery SPAC Opinions
March 7, 2022
Read time: 9 min
Highlighted below are several recent opinions from the Delaware Court of Chancery relating to special purpose acquisition companies (SPACs) that provide helpful guidance to sponsors, investors and practitioners. These cases are a good reminder that well-worn principles of Delaware law still apply in the SPAC context:
- In In re Multiplan Corp. Stockholder Litigation, 2022 WL 24060 (Del. Ch. Jan. 3, 2022), the court, on a motion to dismiss (meaning that inferences are drawn in favor of the plaintiff and claim dismissal is inappropriate unless the plaintiff would not be entitled to recover under any reasonably conceivable set of circumstances), (i) held the entire fairness standard of review (the most onerous standard under Delaware law) applied to a de-SPAC transaction where SPAC fiduciaries (including the sponsor) allegedly suffered from inherent conflicts with public stockholders due to the economic benefit they received in the transaction and (ii) denied dismissal of stockholders’ fiduciary duty claims against those fiduciaries for allegedly making materially misleading disclosures that impaired the stockholders’ ability to make a fully informed decision whether to redeem their stock in connection with the transaction.
- In Brown v. Matterport, Inc., 2022 WL 89568 (Del. Ch. Jan. 10, 2022), the court held that the plain terms of a lock-up provision in a SPAC’s bylaws rendered the lock-up inapplicable to certain of the post-closing stockholders since those stockholders did not receive their post-closing shares “immediately following” the merger transaction, as was required under the lock-up provision. Delaware courts will apply the literal text of a contract (e.g., bylaws) as opposed to what may have been the spirit of the agreement.
- In In re Forum Mobile, Inc., 2022 WL 322013 (Del. Ch. Feb. 3, 2022), the court denied appointment of a custodian over a defunct Delaware corporation (whose shares retained a CUSIP number) where the petitioner intended to revive the corporation in order to access the public markets. Delaware has a long-standing policy against permitting entrepreneurs to manipulate Delaware law for the purposes of reviving defunct Delaware entities with still-extant listings and using them as vehicles to access the public markets.
IN RE MULTIPLAN CORP. STOCKHOLDER LITIGATION
In this case, the SPAC’s initial public stockholders alleged that the SPAC’s sponsor and directors (who were not fully independent of each other and may have been motivated by financial incentives not shared with public stockholders, i.e., founder shares that provided a substantial return only if a business combination transaction closed within 24 months of the SPAC’s initial public offering (IPO)) breached their fiduciary duties by making materially misleading statements or omissions in the SPAC’s proxy statement which robbed the public stockholders’ of their right to make a fully informed decision whether to redeem their shares prior to the transaction.
The SPAC chose MultiPlan Corp. (MultiPlan) as its merger target. The proxy statement informed stockholders of the inherent conflicts of the SPAC’s fiduciaries and informed the stockholders about their ability to redeem their shares, and the stockholders overwhelmingly approved the transaction. Following the merger, it was reported that MultiPlan’s largest customer would be forming a competitor—this was not disclosed in the proxy statement—which resulted in a decline in MultiPlan’s share value and ensuing stockholder litigation.
The court held, on a motion to dismiss, that it was reasonably conceivable that the de-SPAC transaction was subject to the entire fairness standard of review (as opposed to director-friendly business judgment rule) since the sponsor (which held founder shares, a unique economic benefit not shared by the public stockholders) and directors (whose economic interest in, and relationship to, the sponsor rendered them not disinterested and independent) were allegedly conflicted, i.e., the terms of the SPAC incentivized the sponsor and directors to make a bad deal versus no deal at all.
These inherent conflicts allegedly led the fiduciaries to discourage stockholder redemptions even when faced with a value-decreasing deal and, as a result of these conflicts, the sponsor and the directors interfered with the public stockholders’ individual redemption rights by making materially misleading disclosures that impaired the stockholders’ ability to make an informed decision.
The court highlighted that it not addressing “the validity of a hypothetical claim where the disclosure is adequate and the allegations rest solely on the premise that fiduciaries were necessarily interested given the SPAC’s structure,” and also noted that “if public stockholders, in possession of all material information about the target, had chosen to invest rather than redeem, one can imagine a different outcome.”
Takeaway: This decision is a reminder that principles of Delaware law continue to apply in the SPAC context. Key points to remember are that (i) SPAC sponsors (and the directors they appoint) that receive a unique benefit from a de-SPAC transaction, which is not shared by other stockholders, will likely be subject to an entire fairness review, (ii) stockholder redemption rights in a de-SPAC transaction are individual to the stockholder, thus making their claims direct (as opposed to derivative, on behalf of the company) and avoiding the requirement of first having to make a litigation demand upon the board or prove demand futility as a result of a conflicted board, and (iii) whenever stockholders are being asked by the board to take an action (such as a vote), the board has the duty to fully disclose all material information. This case may give stockholders a roadmap to bring fiduciary claims in connection with de-SPAC transactions, but it is also helpful guidance to SPAC sponsors and directors of the need for robust and accurate disclosures regarding the de-SPAC transaction and the SPAC target’s business in order to minimize litigation risk.
BROWN V. MATTERPORT, INC., IN RE FORUM MOBILE, INC.
In this decision, the Delaware Court of Chancery addressed the effectiveness of transfer restrictions (lock-up) imposed on stockholders pursuant to bylaws adopted following the closing of a business combination transaction between a SPAC (the survivor of the business combination, renamed Matterport, Inc. (Matterport)) and Matterport Operating, LLC (Legacy Matterport), in which the SPAC acquired Legacy Matterport and equityholders of Legacy Matterport had the right to receive Matterport stock as consideration.
As a result of the business combination, Legacy Matterport stockholders had the right to receive Matterport shares only after they submitted a letter of transmittal. The Matterport bylaws provided that holders of shares of Matterport common stock issued (i) as consideration for the SPAC business combination or (ii) to directors, officers and employees upon the settlement or exercise of restricted stock units, options or other equity awards outstanding immediately following the closing of the business combination transaction in respect of awards of Legacy Matterport stock outstanding immediately prior to the closing of the business combination transaction were not permitted to transfer any of these “Lockup Shares” for 180 days following the closing.
The plaintiff only received his Matterport shares when he submitted letters of transmittal, more than 100 days after the closing, and therefore he argued that he did not hold Lockup Shares (and was not subject to the lock-up) since he did not hold Matterport shares “immediately following” the transaction. The court agreed with the plaintiff, holding that the plain terms of the bylaws provided that the lock-up only applied to holders of Matterport shares “immediately following” the closing and that, as a matter of law, a period of 100 days was not “immediately following” the closing.
Takeaway: Delaware courts apply the objective theory of contract interpretation to bylaws provisions and will give plain and unambiguous terms their commonly accepted meaning unless the context clearly requires a different one or legal phrases having a special meaning are used. Even though the lock-up provision in this case was likely intended to cover the plaintiff, the literal terms of the bylaws did not in fact accomplish this intent in light of the facts. SPAC sponsors are advised to use precise language when drafting contract terms, including bylaws, and should carefully consider how the mechanics of the proposed transaction may impact deal terms contained in such contracts.
IN RE FORUM MOBILE, INC.
Synergy Management Group LLC (Synergy) petitioned the court to have a custodian appointed for Forum Mobile, Inc. (Forum), a defunct Delaware corporation (whose shares continued to have a CUSIP number allowing them to trade over the counter), pursuant to Section 226(a)(3) of the Delaware General Corporation Law (the DGCL). Section 226(a)(3) of the DGCL provides that any stockholder may petition the court to have a custodian appointed for any corporation that has abandoned its business and has failed within a reasonable time to take steps to dissolve, liquidate or distribute its assets. Synergy desired to have the custodian revive Forum in order to use it as a blank-check company to access public markets.
Since 2002, the Delaware courts have maintained a public policy against permitting entrepreneurs to use Delaware law to revive defunct Delaware entities with public listings in order to access the public markets and evade federal securities laws. The court observed that much has changed since the announcement of that policy and, therefore, the court sought guidance from the Securities and Exchange Commission (SEC) on its position with respect to Synergy’s attempt to use Delaware law to circumvent the federal securities regulatory regime. The SEC took no position on the matter (when it easily could have) but did detail the existing protections for public stockholders under the federal securities laws. The court interpreted the SEC’s decision not to take a position as meaning that Delaware’s public policy could not, in this case, provide a basis for denying Synergy’s petition.
The court ultimately denied Synergy’s petition on the basis that Section 226 of the DGCL limits the authority of a custodian to wind up the affairs of the corporation and terminate its existence, and not to revive a corporation.
Takeaway: While the court based its decision on the application of the provisions of the DGCL allowing for custodianship of an abandoned Delaware corporation (i.e., the custodian’s only power is to wind up and terminate), and not public policy, the court signaled that it is still unwilling to permit parties to utilize Delaware law to circumvent federal securities laws.
